Pharmaceutical - GlaxoSmithKline, Neurological


Popular Filters

1 to 25 of 29 results

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states


UK pharma giant GlaxoSmithKline has agreed to a $105 million settlement with 44 US states and the District…

AdvairFinancialGlaxoSmithKlineLegalMarkets & MarketingNeurologicalPaxilPharmaceuticalRespiratory and PulmonaryUSAWellbutrin

GlaxoSmithKline divests rights to Treximet to Pernix for $250 million


UK pharma giant GlaxoSmithKline will divest all of its rights to migraine drug Treximet (sumatriptan/naproxen…

GlaxoSmithKlineLicensingNeurologicalPernix TherapeuticsPharmaceuticalPozenTreximetUSA

Global epilepsy market to reach $4.5 billion by 2019

Global epilepsy market to reach $4.5 billion by 2019


The epilepsy therapeutics market value in the eight major countries - the USA, Canada, France, Germany,…

EisaiFycompaGlaxoSmithKlineGlobalMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpat

Asia-Pacific epilepsy therapeutics market continues to grow as new drugs emerge


The epilepsy therapeutics market value in the Asia-Pacific region - Australia, China, India and Japan…

Asia-PacificEisaiFycompaGlaxoSmithKlineKeppraMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpatZonegran

Approval of proposals for atomoxetine, sugammadex and to fund baclofen injection in New Zealand

Approval of proposals for atomoxetine, sugammadex and to fund baclofen injection in New Zealand


New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of proposals to amend…

Asia-PacificBridionEli LillyFinancialGlaxoSmithKlineHealthcareLioresal IntrathecalMerck & CoNeurologicalNew ZealandPharmaceuticalStrattera

Analysts recommend GSK after Teva announces Advair generic delay

Analysts recommend GSK after Teva announces Advair generic delay


The delay for the generic version of GlaxoSmithKline’s Advair coupled with the advances in the company’s…

AdvairdarapladibEuropeFinancialGlaxoSmithKlineNeurologicalPharmaceuticalRespiratory and PulmonaryTeva Pharmaceutical Industries

GSK returns IPX066 rights to Impax; Merck & Co and Pfizer link up on diabetes drug


US biotech firm Impax Laboratories (Nasdaq: IPXL) saw its shares fall 2% to $17.32 in premarket trading,…

BiotechnologyDiabetesertugliflozinGlaxoSmithKlineImpax LaboratoriesIPX066LicensingMerck & CoNeurologicalPfizerPharmaceuticalResearch

UK's OFT accuses GlaxoSmithKline of "market abuse"


The UK's Office of Fair Trading (OFT) today (April 19) issued a Statement of Objections to certain pharmaceutical…

AlpharmaEuropeGenericsGlaxoSmithKlineLegalMarkets & MarketingNeurologicalNorton HealthcarePaxilPharmaceuticalPricingSeroxat

Patent briefs: Yaz patent invalid; FDA bars generic OxyContin; Appeals court backs GSK over Arzerra


US generics major Actavis (NYSE: ACT, previously trading as Watson) said yesterday (April 16) that it…

ActavisArzerraBayerGenericsGenmabGlaxoSmithKlineNeurologicalNorth AmericaOncologyOxyContinPatentsPharmaceuticalPurdue PharmaReproductiveYaz

Anti-aging breakthrough could mean new drugs within five years


Drugs that combat aging may be available within five years, following landmark work led by an Australian…


Another stumbling block for Impax Pharma's Rytary


Impax Pharmaceuticals, the branded products division of Impax Laboratories (Nasdaq: IPXL), revealed on…

GlaxoSmithKlineImpax LaboratoriesNeurologicalNorth AmericaPharmaceuticalProductionRegulationRytary

GSK and Canadian researchers claim major step toward an Alzheimer's vaccine


A team of researchers from Canada's Universite Laval, CHU de Quebec, and UK pharma giant GlaxoSmithKline…

GlaxoSmithKlinemonophosphoryl lipid ANeurologicalPharmaceuticalResearchVaccines

Pfizer's Quillivant XR oral suspension now available in USA; GlaxoSmithKline files BLA for albiglutide


Confirming expectations announced when Pfizer (NYSE: PFE) revealed its $680 million acquisition of NextWave…

albiglutideDiabetesGlaxoSmithKlineMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceuticalQuillivantRegulation

NeRRe Therapeutics created to develop NRAs from GSK; GlycoVaxyn deal with GSK


NeRRe Therapeutics was launched in the UK yesterday to develop a portfolio of clinical and pre-clinical…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineGlycoVaxynLicensingNeRReTherapeuticsNeurologicalNovo NordiskPharmaceuticalResearchVaccines

Mayne Pharma to acquire Kapanol in Australia from GlaxoSmithKline for up to A$14.0 million


Australia's Mayne Pharma Group (ASX: MYX) has entered into a binding agreement to acquire Kapanol and…

Asia-PacificGlaxoSmithKlineKapanolMayne PharmaMergers & AcquisitionsNeurologicalPharmaceutical

Research shows diabetes drug rosiglitazone improves memory


Rosiglitazone, the active ingredient of GlaxoSmithKline's diabetes drug Avandia, has shown promise as…


GlaxoSmithKline gives up on XenoPort Horizant collaboration


UK pharma giant GlaxoSmithKline (LSE: GSK) says that it has reached an agreement with US partner XenoPort…


EMA reviews hypothesis on Pandemrix hypothesis; finalizes on NSAIDs and CV events


The European Medicines Agency's Committee on Human Medicinal Products (CHMP) said Friday that it has…

Anti-Arthritics/RheumaticsdiclofenacGlaxoSmithKlineibuprofenInflammatory diseasesNaproxenNeurologicalPandemrixPharmaceuticalRegulationVaccines

Leading dopamine agonists will continue to dominate Parkinson's market


The leading dopamine agonists, pramipexole (Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol/BI-Sifrol,…

Boehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingMirapexNeuproNeurologicalPharmaceuticalRequipRytaryUCB

Research news: dolutegravir; TD-1211; and synaptic modulators


UK pharma giant GlaxoSmithKline (LSE: GSK) and Japanese drugmaker Shionogi (TYO: 4507) have reported…

Anti-viralsdolutegravirGalenea CorpGastro-intestinalsGlaxoSmithKlineLicensingNeurologicalPharmaceuticalRegulationResearchShionogiTD-1211TheravanceZonegran

Final guidance from UK NICE on Tarceva, Tyverb, Herceptin, Zytiga and Botox


UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today published…

AllerganBotoxEuropeGlaxoSmithKlineHerceptinJanssenJohnson & JohnsonNeurologicalOncologyPharmaceuticalPricingRegulationRocheTarcevaTyverbZytiga

FDA clears GlaxoSmithKline's Horizant for PHN


The US Food and Drug Administration (FDA) has approved UK Pharma giant GlaxoSmithKline's (LSE: GSK) Horizant…

GlaxoSmithKlineHorizantNeurologicalNorth AmericaPharmaceuticalRegulationXenoPort

1 to 25 of 29 results

Back to top